Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice (AMBER)

28 oktober 2016 uppdaterad av: Celgene Corporation

Retrospective Observational Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice

This is a national, multicenter, retrospective, observational post-authorization study (EPA-OD) study. The study will be conducted by reviewing the medical records of patients up to the start of the study. In each case, only data from before the start of the study will be obtained in order to ensure they are retrospective in nature, thus reflecting the regular use of nab-paclitaxel in clinical practice and avoiding interference with the physician's clinical practice.

To ensure the observational nature of this study, these data will be collected whenever they are available in the patient's medical record, and so no diagnostic or therapeutic intervention outside regular clinical practice will be used.

Studieöversikt

Status

Avslutad

Betingelser

Detaljerad beskrivning

This is a national, multicenter, retrospective, observational post-authorization study (EPA-OD) study. Investigators will include all consecutive adult patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014). These patients must meet all the inclusion criteria and none of the exclusion criteria established in this protocol.

The primary objective is to describe the effectiveness of nab-paclitaxel in terms of response in early lines of chemotherapy for metastatic breast cancer in routine clinical practice.

This study plans to collect data retrospectively, provided they are available in the patient's medical record and according to routine clinical practice.

Studietyp

Observationell

Inskrivning (Faktisk)

46

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Spanien
      • Madrid, Spanien, 28040
        • Hospital Clínico San Carlos
      • Madrid, Spanien, 28033
        • MD Anderson
      • Madrid, Spanien, 28041
        • Hospital 12 Octubre
      • Madrid, Spanien, 28007:
        • Hospital Gregorio Marañón
      • Madrid, Spanien, 28223
        • Hospital Quirón
      • Murcia, Spanien, 30008
        • Hospital Morales Meseguer
    • Andalucía
      • Jaén, Andalucía, Spanien, 23007
        • Complejo Hospitalario Jaén
    • Aragón
      • Zaragoza, Aragón, Spanien, 50009
        • Hospital Clinico Lozano Blesa
    • Castilla La Mancha
      • Toledo, Castilla La Mancha, Spanien, 45071
        • Hospital Virgen Salud
    • Castilla y León
      • Burgos, Castilla y León, Spanien, 09006
        • Hospital Universitario Burgos
      • Salamanca, Castilla y León, Spanien, 37007
        • Hospital Clinico Salamanca
      • Valladolid, Castilla y León, Spanien, 47005:
        • Hospital Clínico Valladolid
    • Cataluña
      • Barcelona, Cataluña, Spanien, 08035
        • Hospital Vall d´hebron
      • Reus, Cataluña, Spanien, 43204
        • Hospital Universitario San Joan Reus
    • Extremadura
      • Badajoz, Extremadura, Spanien, 06006
        • Hospital Infanta Cristina
      • Badajoz, Extremadura, Spanien, 06011
        • Capio Clideba
    • Galicia
      • Orense, Galicia, Spanien, 32005
        • Complejo Hospitalario Orense
    • Murcia
      • Cartagena, Murcia, Spanien, 30202
        • Hospital Santa Lúcia
    • Navarra
      • Pamplona, Navarra, Spanien, 31008
        • Hospital Navarra

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Adult patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than third-line chemotherapy for metastatic disease between 2012 and 2014 will be enrolled consecutively. In addition, patients must meet the selection criteria established in this protocol.

Beskrivning

Inclusion Criteria:

  • Women ≥18 years of age.
  • Confirmed diagnosis of MBC (stage IV).
  • Breast adenocarcinoma confirmed histologically.
  • HER2-negative according to the American Society of Clinical Oncology (ASCO) and Anatomical Pathology (CAP) criteria for the detection of HER2 in breast cancer.
  • Patients who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease in HER2-negative breast cancer during the period 2012-2014 (3 years) and who have received at least one cycle of treatment.
  • Ability to give informed consent, preferably in writing or orally in front of a witness, before the start of data collection (if it is able to be given).

Exclusion Criteria:

  • Patients with any medical or psychological disorder which in the investigator's opinion might compromise the ability of the patient to give their informed consent.
  • Patients who have received treatment with nab-paclitaxel combined with other chemotherapy agents or anti-angiogenic drugs or tumor-targeting drugs with anti-tumor activity.
  • Patients who have taken part in any clinical trial (interventional) during the study period.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Abraxane® treatment in patients with metastatic breast cancer
Patients diagnosed with HER2-negative MBC who have started treatment with nab-paclitaxel monotherapy no further than the third line of chemotherapy for metastatic disease during the past 3 years (2012-2014) and who give their consent to data collection.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall response rate (ORR)
Tidsram: Up to approximately 8 months
The number of patients who achieve a complete response (CR) or partial response (PR) based on RECIST v1.1 criteria during treatment with nab-paclitaxel until disease progression, the end of treatment or the start of the study, whichever comes first.
Up to approximately 8 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Overall Response Rate (ORR)
Tidsram: Up to approximately 8 months
The number of patients who achieve a complete response (CR) or partial response (PR) during the first 3 treatment cycles with nab-paclitaxel and the corresponding 95% CI will be calculated.
Up to approximately 8 months
Disease control rate (DCR)
Tidsram: Up to approximately 8 months
The percentage of patients with complete response (CR), partial response (PR), or stable disease (SD) for at least 16 weeks, and the corresponding 95% confidence intervals (CI) will be calculated.
Up to approximately 8 months
Time to disease progression (TTP)
Tidsram: Up to approximately 8 months
Is defined as the time from the start of treatment with nab-paclitaxel to disease progression or death due to progression. TTP will be estimated by using the Kaplan-Meier method. The median and confidence interval for the median at 95% reliability (95% CI) will be calculated. In patients who show no disease progression or who have not died, the date of censoring may be the day on which the patient's death is documented, the day of the last follow-up assessment or the day of the last tumor assessment in case the foregoing is not available.
Up to approximately 8 months
Progression-free survival (PFS)
Tidsram: Up to approximately 8 months
Is defined as the time from the start of treatment with nab-paclitaxel to disease progression or death from any cause. PFS will be estimated by using the Kaplan-Meier method. Patients who have shown no disease progression or who have not died at the time of data collection will be censored on the date on which it was last known that no disease progression occurred. The date of censoring may be the day of the last follow-up assessment or the day of the last tumor assessment in case the foregoing is not available.
Up to approximately 8 months
Overall survival (OS)
Tidsram: Up to approximately 8 months
Is defined as the time from the start of treatment with nab-paclitaxel to death from any cause. OS will be estimated by using the Kaplan-Meier method. Patients who have not died at the time of data collection will be censored on the date on which they are last known to be alive. The date of censoring may be the day of the last follow-up assessment or the day of the last tumor assessment in case the foregoing is not available.
Up to approximately 8 months
Adverse Events (AEs)
Tidsram: Up to approximately 8 months
Number of participants with adverse events
Up to approximately 8 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Celgene Corporation

Utredare

  • Studierektor: Lorena Pellín, MD, Celgene Spain

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 januari 2016

Primärt slutförande (Faktisk)

1 augusti 2016

Avslutad studie (Faktisk)

1 augusti 2016

Studieregistreringsdatum

Först inskickad

12 januari 2016

Först inskickad som uppfyllde QC-kriterierna

12 januari 2016

Första postat (Uppskatta)

13 januari 2016

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

1 november 2016

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 oktober 2016

Senast verifierad

1 oktober 2016

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • CEL-CMM-2015-01

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Bröstneoplasmer

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Rwanda

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera